pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,728 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1626Endpoints1274Fierce Biotech601BioSpace596BioPharma Dive480raps202onclive165fda recalls105fda medwatch
therapy area
allOncology11365Rare Disease2825Immunology2602Cardiology2336Pulmonology2001Hematology1920Vaccines1688Psychiatry & CNS1120
  • Trump administration releases Medicaid work-requirement rules, prompting state compliance challenges
    The Morning Rounds newsletter highlighted several health‑policy developments, notably new Medicaid work‑requirement rules and fast‑tracked funding for experimental Ebola vaccines. The Trump admini…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancer
    Celcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…
    Endpoints · 4mo agoPositive readoutPositive↗ source
← prev
page 56 of 70
next →
95
globenewswire health73
fda press55
Ophthalmology888
Endocrinology & Metabolism704
Pain679
Nephrology678
  • Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns
    Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • States tighten rules on corporate telehealth, targeting business structures behind direct-to-consumer care
    Telehealth has grown into a multibillion‑dollar industry, with brands like Hims & Hers and Teladoc becoming widely recognized. Despite their visibility, many patients are unaware that corporate te…
    STAT · 4mo agoRegulatoryNegative↗ source
  • ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
    At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology. Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda)…
    Endpoints · 4mo agoNeutral↗ source
  • Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapy
    Fulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B deal
    Servier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Medicare launches $50/month coverage for Wegovy and Zepbound but withholds cost to taxpayers
    Medicare announced a temporary “GLP-1 Bridge” program that will allow adults 65 and older to receive the obesity treatments Wegovy and Zepbound for $50 a month beginning July 1. The program runs t…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis pill shows high remission rates but cancer cases spark safety worries
    Abivax reported that its experimental oral therapy for ulcerative colitis achieved strong efficacy in a Phase 3 maintenance trial involving 580 patients who had previously responded in shorter stud…
    STAT · 4mo agoNegative readoutNegative↗ source
  • ASCO Highlights Barriers to Cancer Care and New Treatments Amid Memorable Pancreatic Cancer Study Ovation
    The annual ASCO meeting featured extensive discussion of the obstacles patients face in accessing cancer care and showcased a range of emerging therapies. STAT compiled a quick‑take newsletter tha…
    STAT · 4mo agoNeutral↗ source
  • Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line study
    Revolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑lin…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectations
    The latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients. In parallel, a lung cancer treatment de…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billion
    French pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…
    STAT · 4mo agoDealPositive↗ source
  • AstraZeneca reports promising triplet therapy results in liver cancer subgroup
    AstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Eli Lilly gives hospitals five days to submit 340B claims data or lose discount pricing
    Eli Lilly has issued a notice to more than 1,000 hospitals that take part in the federal 340B drug discount program, requiring them to provide comprehensive claims data within five days. The compa…
    STAT · 4mo agoRegulatoryNegative↗ source
  • CEPI allocates $62 million to accelerate three Bundibugyo Ebola vaccine candidates
    CEPI announced it will provide roughly $62 million to three groups to speed the development of vaccines targeting the Bundibugyo strain of Ebola, which is currently spreading in the Democratic Repu…
    STAT · 4mo agoDealPositive↗ source
  • Medicare withholds cost data for senior GLP-1 obesity drugs as Massachusetts sues UnitedHealth
    Medicare announced that seniors can obtain Wegovy and Zepbound for $50 a month starting in July, but the agency has not disclosed how much the program will cost taxpayers. The absence of cost tran…
    STAT · 4mo agoRegulatoryNegative↗ source
  • J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer study
    Johnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy Lin
    At the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…
    STAT · 4mo agoNeutral↗ source
  • RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo Therapeutics
    RallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Croatian researcher’s five-decade quest to uncover BPC-157’s potential draws FDA attention
    In 1975 a second‑year medical student at the University of Zagreb heard a lecture on stress and the stomach lining. He imagined the organ produced a natural anti‑stress chemical and set out to find…
    STAT · 4mo agoNeutral↗ source
  • FDA misses self-imposed deadline on electric shock device ban, prompting disability advocates' outcry
    The Food and Drug Administration did not issue a decision by the end of May as it had set for itself on whether to prohibit electrical shock devices used on people with intellectual disabilities an…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Hospitals grapple with patient requests for unvaccinated donor blood
    Some patients are now asking hospitals to provide blood that comes only from donors who have not received any COVID-19 vaccine, creating a new set of ethical and logistical questions. The demand r…
    STAT · 4mo agoNeutral↗ source
  • New No Surprises Act arbitration rule may increase provider disputes, critics say
    The administration released a final rule on Thursday that tweaks the No Surprises Act arbitration process. The changes are meant to improve communication between insurers and providers and give Med…
    STAT · 4mo agoRegulatoryNegative↗ source
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    Endpoints · 4mo agoNeutral↗ source